Goldman Keeps Halozyme at Sell, Sets $58 Target Despite Strong Guidance and Strategic Deals
Goldman Sachs has maintained a Sell rating on Halozyme Therapeutics with a $58 price target, a mark well below the current share price. The firm’s view reflects concerns about royalty revenue durability beyond 2029, even as Halozyme reported robust near-term growth, raised multi-year revenue guidance and disclosed strategic acquisitions and partner…